AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for Lysophospholipase D GDPD1

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.

We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.

Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.

We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.

 Fig. 1. The sreening workflow of Receptor.AI

The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.

Our library distinguishes itself through several key aspects:

  • The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.
  • The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.
  • The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.
  • In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.

partner

Reaxense

upacc

Q8N9F7

UPID:

GDPD1_HUMAN

Alternative names:

Glycerophosphodiester phosphodiesterase 4; Glycerophosphodiester phosphodiesterase domain-containing protein 1

Alternative UPACC:

Q8N9F7; A8W735; Q56VR1; Q8N4E3

Background:

Lysophospholipase D GDPD1, also known as Glycerophosphodiester phosphodiesterase 4, plays a crucial role in lipid metabolism by hydrolyzing lysoglycerophospholipids to produce lysophosphatidic acid (LPA) and corresponding amines. It shows a preference for substrates like lyso-PAF, lyso-PE, and lyso-PC, and is involved in bioactive N-acylethanolamine biosynthesis. This enzyme's specificity towards certain phospholipids underlines its importance in cellular lipid remodeling and signaling.

Therapeutic significance:

Understanding the role of Lysophospholipase D GDPD1 could open doors to potential therapeutic strategies.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.